Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Operating Leases (2023 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Operating Leases for 3 consecutive years, with $7.9 million as the latest value for Q2 2025.

  • On a quarterly basis, Operating Leases changed N/A to $7.9 million in Q2 2025 year-over-year; TTM through Jun 2025 was $7.9 million, a N/A change, with the full-year FY2024 number at $8.3 million, down 6.77% from a year prior.
  • Operating Leases was $7.9 million for Q2 2025 at Centessa Pharmaceuticals, down from $8.3 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $8.9 million in Q4 2023 to a low of $7.9 million in Q2 2025.
  • A 3-year average of $8.4 million and a median of $8.3 million in 2024 define the central range for Operating Leases.
  • Biggest YoY gain for Operating Leases was 6.77% in 2024; the steepest drop was 6.77% in 2024.
  • Centessa Pharmaceuticals' Operating Leases stood at $8.9 million in 2023, then decreased by 6.77% to $8.3 million in 2024, then fell by 4.18% to $7.9 million in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Operating Leases are $7.9 million (Q2 2025), $8.3 million (Q4 2024), and $8.9 million (Q4 2023).